1048360-18-4

Upstream product

• 186698-61-3 (S)-2-(tert-butoxycarbonylamino)-5-(3-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)pentanoic acid 
• 19023-94-0 (2-aminoethyl)-methylcarbamic acid,benzyl ester 
• 1221593-52-7 methyl-[2-(2,2,2-trifluoro-acetylamino)-ethyl]carbamic acid benzyl ester 
• 200124-22-7 Boc-Arg-(Pbf)-OH 
• 162576-01-4 2-(aminoethyl)methylcarbamic acid benzyl ester hydrochloride 

Downstream Products

• 1048360-17-3 {2-[H-Arg(Pbf)]aminoethyl}methylcarbamic acid benzyl ester 
• 1276122-67-8 {2-[2-tert-butylmalonyl-Arg(Pbf)]aminoethyl}methylcarbamic acid benzyl ester 
• 1345532-64-0 N-((S)-1-(2-([3-((1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenoxycarbonyl]-methyl-amino)-ethylcarbamoyl)-4-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-guanidino)-butyl)-malonamic acid tert-butyl ester 
• 1345532-66-2 N-[(S)-1-(2-([3-((1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenoxycarbonyl]-methyl-amino)-ethylcarbamoyl)-4-guanidino-butyl]-malonamic acid trifluoroacetate 

Relevant academic research and scientific papers

Pharmaceutical compositions with attenuated release of phenolic opioids

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with th

An enzyme and its optional [...] modified ketone and inhibitor composition comprising (by machine translation)

PROBLEM TO BE SOLVED: ketone-containing acrylic misuse, abuse or overload is prevented for a new takable amt. provitamin drag pain. SOLUTION: a compound represented by the following formula is represented, in which the drag oxystyrene provitamin hydrocodone ketone-containing acrylic. Pre-selected drug profile is modified and the ketone and schisandrin [...] holding hung contg. compsn. method for administration to a patient. Selected drawing: no (by machine translation)

Active agent prodrugs with heterocyclic linkers

The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.